CD8A and neoplasm: Though AML with RUNX1::RUNX1T1 patients were used as an example to explore, we also obtained consistent conclusions in other AML subtypes, suggesting that ADGRG1 could become a potential unified marker of CD8+ tumor-reactive T cells within AML.